Clinical trials: Lymphatic Disorders
Sickle Cell Disease
Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
The purpose of this study is to assess the safety and tolerability of HQK-1001 administered for a total of 12 weeks (with one dosing break) in subjects with sickle cell disease.
- Trial name
- NCT00842088
- Testing
- HQK-1001
- Where
- 9 sites in United States, Jamaica
- Volunteers
- 24 people
- Sponsor
- HemaQuest Pharmaceuticals Inc.
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
MDS, Cardiovascular Diseases
Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia
This study evaluates the relationship between myelodysplastic syndromes (MDS) and cardiovascular disease. MDS patients will be evaluated for the presence of mutations and whether they are associated with an increased risk of…
- Conditions
- MDS, Cardiovascular Diseases, Inflammation
- Trial name
- NCT04110925
- Testing
- Genetic Mutations, Inflammatory and lipid markers, Computed Tomography (CT) of the heart
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- Sunnybrook Health Sciences Centre
Lymphoma, Non-Hodgkin, Lymphoblastic Lymphoma, Childhood
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With LBL
With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoblastic Lymphoma, Childhood, PTEN Loss, NOTCH1 Gene Mutation
- Trial name
- NCT03971318
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Thalassemia Trait, Thalassemia; Mixed
Thalassemia Screening by Third Generation Sequencing
Test globin gene in participants
- Trial name
- NCT05552690
- Testing
- blood draw
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- Chiang Mai University
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute
MSC and HSC Coinfusion in Mismatched Minitransplants
The present project aims at evaluating the capacity of MSC to improve one-year overall survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors after non-myeloablative conditioning.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic, Myeloproliferative Disorders
- Trial name
- NCT01045382
- Testing
- Mesenchymal stem cells, Isotonic solution
- Where
- 10 sites in Belgium
- Volunteers
- 39 people
- Sponsor
- University of Liege
Pediatrics, Solid Tumors
This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas
This is a Phase 1 study of eribulin mesylate in pediatric participants with recurrent or refractory solid tumors (excluding CNS), including lymphomas.
- Trial name
- BOLD 113 (NCT02171260)
- Testing
- Eribulin Mesylate
- Where
- 18 sites in United States
- Volunteers
- 23 people
- Sponsor
- Eisai Inc.
Acute Lymphoblastic Leukemia
Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia
Primary objective : To explore the relation between 3 doses of GRASPA and duration of asparagine depletion (< 2µmol/l) Secondary objective : Pharmacokinetic / Pharmacodynamic parameters toxicity Study duration : 2 years Study…
- Trial name
- GRASPALL (NCT00723346)
- Testing
- GRASPA, native L asparaginase
- Where
- France
- Volunteers
- 25 people
- Sponsor
- ERYtech Pharma
Atypical Hemolytic Uremic Syndrome
Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS
Atypical hemolytic syndrome (aHUS) is a severe renal disease affecting children and adults. It is characterized by the occlusion of intrarenal vessels due to the presence of platelet/fibrin thrombi, and leads to end-stage renal…
- Trial name
- STOPECU (NCT02574403)
- Testing
- eculizumab
- Where
- 22 sites in France
- Volunteers
- 58 people
- Sponsor
- Nantes University Hospital
Solid Tumors, Hematologic Malignancies
Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.
- Trial name
- NCT02457962
- Where
- United States
- Volunteers
- 15,000 people
- Sponsor
- Mayo Clinic
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitts Leukemia/Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT01513603
- Testing
- CLAG-M
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- New York Medical College
Hematopoietic Malignancy, Relapse/Recurrence
TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
About 33% of patients with myeloid or lymphoid malignancies experience relapse with HLA loss after haplo-HSCT. Due to the specificity of HLA-loss relapse, the 2019 European Society for Blood and Marrow Transplantation (EBMT)…
- Conditions
- Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06125483
- Testing
- Umbilical Cord Blood Transplantation
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Myelofibrosis
A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey
This was a non-interventional retrospective study. Data from patients who were diagnosed with myelofibrosis (MF) (primary MF, post-polycythemia vera MF \& post-essential thrombocythemia MF) and treated with ruxolitinib for at…
- Trial name
- NCT07357441
- Where
- United States
- Volunteers
- 355 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Primary Cutaneous Follicle Centre Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT03999697
- Testing
- Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Sickle Cell Disease, Thalassemia
Use of Mobile Technology for Intensive Training in Medication Management
Purpose: Assess whether intensive training with education and daily remote monitoring with provider involvement has a lasting positive impact on adherence to medication management.
- Trial name
- NCT02133560
- Testing
- Video recording, Medication Administration Log, Education
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Duke University
Severe Aplastic Anemia
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
Background: Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells.
- Trial name
- NCT04304820
- Testing
- Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Leukemias, Chronic Leukemias
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Long-term follow-up studies have demonstrated significant late toxicities of total body irradiation (TBI), which are most marked in children radiated at a young age.
- Conditions
- Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT01339988
- Testing
- Busulfan/Cyclophosphamide
- Volunteers
- 10 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Blood Transfusion Complication, Wrong Blood in Tube
Proficiency Based Training to Investigate Blood Sampling Errors Including WBIT
The objective of this study is to determine the effectiveness of a Proficiency Based Progression training programme, together with evidence based individual feedback for any residual errors, which has been specifically developed…
- Conditions
- Blood Transfusion Complication, Wrong Blood in Tube, Pre Analytical Blood Sample Errors
- Trial name
- NCT03577561
- Testing
- Proficiency Based Progression Training in Phlebotomy
- Where
- Ireland
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Patrick Henn
Lymphoma, Leukemia
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Background: Patients with cancers of the blood and immune system often benefit from transplants of stem cells from a genetically well-matched sibling.
- Conditions
- Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma
- Trial name
- NCT00074490
- Testing
- Rituximab, Fludarabine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
ALL, B Cell Lymphoma
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Background: Although progress has been made in treating children with B-cell cancers such as leukemia or lymphoma, many children do not respond to the standard treatments.
- Conditions
- ALL, B Cell Lymphoma, Leukemia, Large Cell Lymphoma
- Trial name
- NCT01593696
- Testing
- Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.